

The NIH should ensure that proposals for training grants and center grants include appropriate provisions for training and technical assistance in the issues discussed in this report. Where appropriate, the NIH and the Office for Protection from Research Risks (OPRR) should consider using consensus development conferences or workshops to advance discussion of these issues.

Institute of Medicine Review of Research Studies

*Recommendation 20.* The Department of Health and Human Services should contract with the Institute of Medicine to conduct a comprehensive review and evaluation of the nature and extent of challenge, washout, and placebo controlled studies with subjects with mental disorders that may affect decisionmaking capacity.

Increased Funding To Support Necessary Protections of Human Subjects

*Recommendation 21.* Compliance with the recommendations set forth in this report will require additional resources. All research sponsors (government, private sector enterprises, and academic institutions) should work together to make these resources available.

**FOR FURTHER INFORMATION ABOUT THE REPORT CONTACT:** Eric M. Meslin, Ph.D., Executive Director, National Bioethics Advisory Commission or to obtain copies of the report contact: Ms. Patricia Norris, National Bioethics Advisory Commission, 6100 Executive Boulevard, Suite 5B01, Rockville, Maryland 20892-7508, telephone 301-402-4242, fax number 301-480-6900. Copies may also be obtained through the NBAC website: [www.bioethics.gov](http://www.bioethics.gov).

Dated: February 12, 1999.

**Eric M. Meslin,**

*Executive Director,*

*National Bioethics Advisory Commission.*

[FR Doc. 99-4190 Filed 2-18-99; 8:45 am]

BILLING CODE 4160-17-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Healthcare Infection Control Practices Advisory Committee (formerly Hospital Infection Control Practices Advisory Committee), Notice of Charter Renewal

This gives notice under the Federal Advisory Committee Act (Public Law 92-463) of October 6, 1972, that the Healthcare Infection Control Practices

Advisory Committee (HICPAC), National Center for Infectious Diseases (NCID), of the Department of Health and Human Services, has been renewed for a 2-year period through January 19, 2001.

For information, contact Michele Pearson, M.D., Executive Secretary, HICPAC, NCID, CDC, 1600 Clifton Road, m/s A07, Atlanta, Georgia 30333. Telephone 404/639-6400.

The Director, Management Analysis and Services Office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: February 11, 1999.

**Carolyn J. Russell,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 99-4089 Filed 2-18-99; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[Program Announcement 99017]

#### Evaluating Potential Exposures To Blood and Risk of Hepatitis C Virus (HCV) Infection Among Persons Without Traditional Risk Factors; Notice of Availability of Funds

##### A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 1999 funds for a cooperative agreement program for evaluating potential exposures to blood and risk of hepatitis C virus (HCV) infection among persons without traditional risk factors. This program addresses the "Healthy People 2000" priority area of Immunization and Infectious Diseases. The purpose of the program is to provide assistance for addressing the risk of HCV or hepatitis B virus (HBV) transmission through potential but unproven mucosal or percutaneous exposures to blood in the United States. Specifically, applications are solicited for projects aimed at determining if there is an increased risk of HCV or HBV infection associated with illegal intranasal drug use (e.g., cocaine or heroin), anabolic steroid abuse, tattooing, or body piercing in populations with a low prevalence of illegal injection drug use.

##### B. Eligible Applicants

Applications may be submitted by public and private nonprofit organizations and by governments and their agencies, that is, universities, colleges, research institutions, hospitals, other public and private nonprofit organizations, State and local governments or their bona fide agents, and federally recognized Indian tribal governments, Indian tribes, or Indian tribal organizations.

**Note:** Public Law 104-65 states that an organization described in section 501(c)(4) of the Internal Revenue Code of 1986 that engages in lobbying activities is not eligible to receive Federal funds constituting an award, grant, cooperative agreement, contract, loan, or any other form.

##### C. Availability of Funds

Approximately \$150,000 is available in FY 1999 to fund one award. It is expected that the award will begin on or about June 1999 and will be made for a 12-month budget period within a project period of one year. The funding estimate may change.

##### D. Program Requirements

In conducting activities to achieve the purpose of this program, the recipient will be responsible for the activities under (Recipient Activities), and CDC will be responsible for the activities listed under (CDC Activities).

##### Recipient Activities

1. Conduct research to determine if there is a risk of HCV or HBV infection, independent of known risk factors for transmission, associated with percutaneous exposures, such as tattooing, body piercing, or illegal injection of anabolic steroids, or permucosal exposures, such as use of illegal intranasal drugs.

2. Develop a study protocol to determine the prevalence of potential exposures for bloodborne pathogen transmission (i.e., illegal intranasal drug use, anabolic steroid abuse, tattooing, body piercing) in populations with a low prevalence of illegal injection drug use and their prevalence of HCV and HBV infection.

3. Based on the protocol, conduct an epidemiologic study of the potential association between HCV or HBV infection and illegal intranasal drug use, anabolic steroid abuse, tattooing, and body piercing.

4. Analyze, interpret, and publish results.

##### CDC Activities

1. Upon request of recipient, provide technical assistance in the design, conduct, and analysis of the research,